Alpha Teknova, Inc. (TKNO)

Market Cap	412.07M
Revenue (ttm)	36.35M
Net Income (ttm)	-31.68M
Shares Out	53.31M
EPS (ttm)	-0.73
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	318,025
Open	7.28
Previous Close	7.24
Day's Range	7.28 - 8.08
52-Week Range	1.16 - 8.91
Beta	0.38
Analysts	Buy
Price Target	5.00 (-35.32%)
Earnings Date	Nov 7, 2024

About TKNO

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 211
• Stock Exchange: NASDAQ
• Ticker Symbol: TKNO
• Website: https://www.teknova.com

Financial Performance

In 2023, Alpha Teknova's revenue was $36.68 million, a decrease of -11.43% compared to the previous year's $41.42 million. Losses were -$36.78 million, -22.52% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for TKNO stock is "Buy." The 12-month stock price forecast is $5.0, which is a decrease of -35.32% from the latest price.

Price Target

$5.0

(-35.32% downside)

Analyst Consensus: Buy